首页 / 院系成果 / 成果详情页

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis 期刊论文

编号：

EF6C7300B5AC5DC1718F6CC00C2A2D74
作者：

Zhang, Yuan#^{[1,2,3,4,5,6]}Li, Jingyun#^[2,3,4,5,6]Li, Xian^{[1,2,3,4,5,6]};Wang, Menglin^[2,3,4,5,6];Yang, Xiangli^[7];Shi, Li^[8,9,10];Cao, Zhiwei^[11];Feng, Yan;Liu, Weiwei^[12];Xu, Zhendong^[13];Ma, Ruixia^[14];Gao, Xiaoping^[15];Liu, Wen^[16];Xue, Jinmei^[17];Ren, Xiaoyong^[18];Li, Xuezhong^[19];Song, Xicheng^[20,21];Yang, Yi^[22,23];Quan, Fang^[24,25];Cheng, Lei^[26,27];Jiang, Weihong^[28];Li, Huabin^[29];Li, Jian^[30];Liu, Huanhai^[31];Liu, Jianfeng(刘剑锋)^[32]Liu, Zheng^[33];Lv, Wei^[34];Qiu, Qianhui^[35];Wang, Xiangdong^[2];Xu, Yu^[36];Xu, Yuanteng^[37,38,39];Yang, Qintai^[40];Yang, Yucheng^[41];Ye, Jing^[42];Yu, Hongmeng^[43,44];Zhu, Dongdong^[45];Wang, Chengshuo*^[2,3,4,5,6]Zhang, Luo*^{[1,2,3,4,5,6]}
语种：

英文
期刊：

ALLERGY ISSN：0105-4538 2026 年 ; 2026 MAR 23
收录：
关键词：

allergic rhinitis biologics China monoclonal antibody treatment
摘要：

Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to treat patients experiencing poorly controlled symptoms, despite standard-of-care (SoC) treatment. Although biological treatment options for AR remain limited worldwide, the recent approval of novel agents, such as stapokibart for seasonal allergic rhinitis (SAR), has accelerated clinical research and development in this field. Evidence for biologic therapy in the management of perennial allergic rhinitis (PAR) is currently sparse. To standardise the use of biologics in AR management and promote their evidence-based application, a multidisciplinary expert panel was convened. This position paper evaluates current evidence regarding the efficacy and safety of biologic agents for AR, incorporating data from both international and regional clinical studies. Here, we provide recommendations on appropriate indications for biologic therapy and emphasise its role in patients with uncontrolled SAR, supporting clinical decision-making and facilitating the integration of biologics into routine practice.
推荐引用方式
GB/T 7714：

Zhang Yuan,Li Jingyun,Li Xian, et al. Chinese Position Paper on Biologic Therapy for Allergic Rhinitis [J].ALLERGY,2026.
APA：

Zhang Yuan,Li Jingyun,Li Xian,Wang Menglin,&Zhang Luo.(2026).Chinese Position Paper on Biologic Therapy for Allergic Rhinitis .ALLERGY.
MLA：

Zhang Yuan, et al. "Chinese Position Paper on Biologic Therapy for Allergic Rhinitis" .ALLERGY(2026).
入库时间：

2026/4/1 9:56:06
更新时间：

2026/4/1 9:56:06
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：7  下载次数：0

分享到：

浏览次数：7

下载次数：0

打印次数：0